Another feather to the cap: Patent approval in Europe

It gives us immense joy to share with our readers that we have been granted patent on our technology ReLink® in Europe. ReLink® is a patented breakaway connector, designed and engineered to increase safety and reduce harm caused by accidental dislodgement incidents.

Covid-19 forces us to emphasise on things we already knew were important Many healthcare markets are already trending towards homecare and digital healthcare since it relieves some of the strain that is placed on hospitals.

ReLink® has the potential to prove market in such scenarios. ReLink® is specially engineered to enhance infusion stability by keeping connections of IV cannula to IV lines, with a controlled break away and predictable results. ReLink® not only reduces the patient harm but also the nursing time which can prove to be beneficial during treatment of highly infectious patients, such as COVID-19.


Related Posts

See All

Tada Medical AB

keeping connections

Regeringsgatan 82
111 39 Stockholm, Sweden

  • Tada Medical AB Facebook Handle
  • Tada Medical AB LinkedIn Handle
  • Tada Medical AB YouTube Handle
  • Tada Medical AB Instagram Handle

© 2021 by Tada Medical AB  |  All rights reserved